Abstract: Provided are non-naturally occurring 5?-untranslated region and 3?-untranslated region nucleotides, and use thereof.

Abstract: Proposed is a dual scan-type ion implant system including a process chamber, first and second scan robots, and an EFEM. In the process chamber, scanning is performed with an ion beam. The first and second scan robots are placed inside the process chamber. The EFEM is provided on one side of the process chamber, and is equipped with a plurality of wafer cassettes. The first and second scan robots inside the process chamber receive wafers from the EFEM along different non-overlapping wafer scan transfer paths, respectively, and then the first and second scan robots alternately perform ion beam scanning.

Abstract: Provided is a method and an apparatus for targeting an object in a game. The method of targeting an object in a game includes: setting a center point of a first targeting area based on a first input from a user; displaying the first targeting area surrounded by a closed curve around the center point on a screen of a user terminal; displaying a list including at least one object located in the first targeting area on the screen; and moving the first targeting area based on a second input by the user received after the first input.

Abstract: Disclosed are oxadiazole compounds and pharmaceutically acceptable salts thereof. The compounds and pharmaceutically acceptable salts thereof are specifically suitable for the treatment of neurological diseases such as epilepsy.

Abstract: A multilayer electronic component includes a body including a capacitance formation portion including a dielectric layer and internal electrodes alternately disposed in a first direction, and a cover portion disposed on both surfaces of the capacitance formation portion opposing each other in the first direction; and an external electrode disposed on the body and connected to the internal electrode, wherein the cover portion includes polydopamine.

Abstract: A coil component includes a body having one surface and the other surface, opposing each other, both lateral surfaces respectively connecting the one surface and the other surface and opposing each other, and both end surfaces respectively connecting the both lateral surfaces and opposing each other; a coil unit disposed in the body; a first external electrode and a second external electrode, respectively connected to the coil unit and disposed to be spaced apart from each other on the one surface of the body; and a first insulating layer covering the other surface of the body, the both lateral surfaces of the body, and the both end surfaces of the body.

Abstract: Provided is a pharmaceutical composition for preventing or treating Asherman's syndrome or complications thereof, comprising mitochondria as an active ingredient. The pharmaceutical composition alleviates or treats endometrial adhesion, and may alleviate or treat endometrial fibrosis. Therefore, the pharmaceutical composition may be effectively used in the treatment and prevention of diseases such as endometrial adhesion disease, particularly Asherman's syndrome, and thus is highly industrially applicable.

Abstract: A polishing composition and method for semiconductor processing being applicable to a semiconductor process including a process of polishing a semiconductor wafer including a through-silicon via (TSV), being capable of implementing excellent polishing performance, being capable of minimizing defects such as dishing, erosion, and protrusion, being capable of realizing an evenly polished surface without deviation between films when polishing a surface where a plurality of different films is exposed to the outside, including abrasive grains and at least one additive, and having a value of 1.45 to 1.90 as calculated by Equation 1.

Abstract: The present invention relates to a method for extracting collagen from a liposuction effluent, wherein collagen is extracted by treating a collagen-containing liposuction effluent in the presence of a supercritical fluid. According to the present invention, conventionally discarded collagen in a liposuction effluent can be extracted at high purity, and the extracted high purity collagen can be widely used in medical, pharmaceutical, and cosmetic products.

Abstract: The present invention relates to a pharmaceutical composition for the treatment of sepsis or systemic inflammatory response syndrome (SIRS) comprising mitochondria as effective ingredient. When activated macrophages and monocytes are treated with mitochondria which are effective ingredient of the pharmaceutical composition of the present invention, expression of IL-1?, TNF-? and IL-6 which are pro-inflammatory cytokines can be restored to normal levels. Furthermore, when the pharmaceutical composition of the present invention is administered to a subject suffering from sepsis, the survival rate of the subject can be remarkably increased. Therefore, the pharmaceutical composition according to the present invention can be useful for the treatment of sepsis.

Abstract: Disclosed are a pharmaceutical composition containing isolated mitochondria as an effective component and uses of the composition. The pharmaceutical composition can restore the ATP synthesis capacity and antioxidant capacity of tenocytes damaged by inflammations to a normal tenocyte level. In addition, the pharmaceutical composition, when administered to damaged tenocytes, inhibits the expression of an apoptosis promoter, Bax, and increases the expression of an apoptosis inhibitor, Bcl-2. In addition, the pharmaceutical composition, when administered to damaged tenocytes, can restore the expression of MMP1 to a normal tenocyte level. Accordingly, uses of the pharmaceutical composition include prevention or treatment of tendinopathy in a subject.

Abstract: The present invention relates to a method for extracting collagen from liposuction effluent, wherein collagen is extracted by treating collagen-containing liposuction effluent in the presence of a supercritical fluid. According to the present invention, conventionally discarded collagen in liposuction effluent can be extracted at high purity, and the extracted high purity collagen can be widely used in medical, pharmaceutical, and cosmetic products.

Abstract: Mitochondria modified by a targeting protein, according to one embodiment of the present invention, can be effectively delivered to a target. In addition, when a protein of interest bound to the modified mitochondria is delivered into a cell, various activities can be exhibited. The modified mitochondria can effectively cause cancer tissue death, and thus can also be used as an anticancer agent. Furthermore, various activities are exhibited according to a protein of interest loaded on modified mitochondria, and thus the modified mitochondria can be applied in the treatment of various diseases. Additionally, a fusion protein comprising a protein of interest and a fusion protein comprising a targeting protein, according to one embodiment of the present invention, can be used in order to modify mitochondria. Moreover, mitochondria modified with the fusion proteins exhibits various effects in a target cell.

Abstract: The present invention relates to a pharmaceutical composition for prevention or treatment of rheumatoid arthritis and, more particularly, to a pharmaceutical composition comprising mitochondria as an effective ingredient for prevention or treatment of rheumatoid arthritis. When a foreign mitochondria pharmaceutical composition of the present invention is administered to a subject suffering from rheumatoid arthritis, the subject may alleviate edema and rubefaction symptoms. In addition, the pharmaceutical composition of the present invention reduces an expression level of the inflammatory cytokine IL-6, but increases an expression level of the anti-inflammatory cytokine IL-10 in the subject. Therefore, the pharmaceutical composition according to the present invention can be effectively used for preventing or treating rheumatoid arthritis.

Abstract: A ferroelectric semiconductor device of the present disclosure includes a substrate, a ferroelectric layer disposed on the substrate, an electric field control layer that is disposed on the ferroelectric layer and has a predetermined internal electric field formed without the application of an external electric power to alter the magnitude of a coercive electric field of the ferroelectric layer, and a gate electrode layer disposed on the electric field control layer.

Abstract: In an embodiment, a ferroelectric memory device includes a semiconductor substrate, a first ferroelectric memory cell transistor of NMOS type disposed in a first region of the semiconductor substrate, and a second ferroelectric memory cell transistor of PMOS type disposed in a second region adjacent to the first region of the semiconductor substrate. A first gate electrode layer of the first ferroelectric memory cell transistor and a second gate electrode layer of the second ferroelectric memory cell transistor are electrically connected to each other.

Abstract: A neuromorphic device is provided. The neuromorphic device may include a pre-synaptic neuron; a row line extending in a row direction from the pre-synaptic neuron; a post-synaptic neuron; a column line extending in a column direction from the post-synaptic neuron; and a synapse disposed at an intersection between the row line and the column line. The synapse may include a first synapse layer including a plurality of first carbon nano-tubes; a second synapse layer including a plurality of second carbon nano-tubes having different structures from the plurality of first carbon nano-tubes; and a third synapse layer including a plurality of third carbon nano-tubes having different structures from the plurality of first carbon nano-tubes and the plurality of second carbon nano-tubes.

Abstract: The present invention relates to a pharmaceutical composition containing mitochondria and, more specifically, to a pharmaceutical composition for preventing or treating muscle diseases or ischemic diseases, containing mitochondria as active ingredients. The pharmaceutical composition of the present invention contains heterologous mitochondria or cells comprising heterologous mitochondria, thereby enabling the mitochondrial activity of cells to which the same is administered to improve. Therefore, the pharmaceutical composition according to the present invention can be useful in the fundamental prevention or treatment of muscle diseases or ischemic diseases, which occur in relationship with the deterioration of mitochondrial function.

Abstract: A ferroelectric semiconductor device of the present disclosure includes a substrate, a ferroelectric layer disposed on the substrate, an electric field control layer that is disposed on the ferroelectric layer and has a predetermined internal electric field formed without the application of an external electric power to alter the magnitude of a coercive electric field of the ferroelectric layer, and a gate electrode layer disposed on the electric field control layer.

Abstract: In an embodiment, a ferroelectric memory device includes a semiconductor substrate, a first ferroelectric memory cell transistor of NMOS type disposed in a first region of the semiconductor substrate, and a second ferroelectric memory cell transistor of PMOS type disposed in a second region adjacent to the first region of the semiconductor substrate. A first gate electrode layer of the first ferroelectric memory cell transistor and a second gate electrode layer of the second ferroelectric memory cell transistor are electrically connected to each other.